Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Morphic Holding Inc.
Headquarters: Waltham, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Oct 14, 2024
Deals
Lundbeck bolts on Longboard, gains anticonvulsive in $2.6B deal
Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies
BioCentury | Jul 31, 2024
Data Byte
I&I buying spree continues
2024 has already brought half a dozen M&A deals over $1B targeting immunology and inflammation
BioCentury | Jul 12, 2024
Finance
Still not over the hump, as biotech heads into 2H24
3Q24 Public Markets Preview: Conviction is the buzzword as investors weigh new opportunities
BioCentury | Jul 8, 2024
Deals
Deals report: Lilly acquires Morphic, GSK gets full rights for mRNA vaccines from CureVac
Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Apr 22, 2024
Finance
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Jan 4, 2024
Management Tracks
Lanthaler leaving Evotec as CEO
Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella
BioCentury | Sep 27, 2023
Management Tracks
Morphic CEO Tipirneni taking medical leave of absence
Plus: David Stack to retire as chair, CEO of Pacira and updates from AM-Pharma, Invitae, Syneos and Faeth
BioCentury | Sep 22, 2023
Product Development
Sept. 22 Quick Takes: Daiichi-AZ’s TROP2 ADC meets PFS endpoint in Phase III
Plus: Padcev meets in Phase III for broader urothelial cancer population, and updates from Merck-Eisai, Abpro, Lilly-Boehringer, Abpro, Morphic and more
Items per page:
1 - 10 of 30